metformin has been researched along with hydroxycitric acid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McCarty, MF | 2 |
| Abolhassani, M; da Veiga Moreira, J; Hamraz, M; Jolicœur, M; Peres, S; Schwartz, L | 1 |
3 other study(ies) available for metformin and hydroxycitric acid
| Article | Year |
|---|---|
Utility of metformin as an adjunct to hydroxycitrate/carnitine for reducing body fat in diabetics.
Topics: Adipose Tissue; Body Composition; Carnitine; Citrates; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Models, Biological; Obesity; Weight Loss | 1998 |
AMPK activation as a strategy for reversing the endothelial lipotoxicity underlying the increased vascular risk associated with insulin resistance syndrome.
Topics: Adipocytes; Adiponectin; AMP-Activated Protein Kinases; Cardiovascular Diseases; Citrates; Diabetes Complications; Dietary Fats; Diglycerides; Endothelium, Vascular; Enzyme Activation; Fatty Acids, Nonesterified; Glycerol-3-Phosphate O-Acyltransferase; Humans; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Metformin; Models, Biological; Multienzyme Complexes; Obesity; Oxidation-Reduction; Protein Kinase C; Protein Serine-Threonine Kinases; Risk; Sterol Esterase | 2005 |
Metabolic therapies inhibit tumor growth in vivo and in silico.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carbon; Carcinogenesis; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Proliferation; Citrates; Diclofenac; Energy Metabolism; Glucose; Heterografts; Humans; Lactic Acid; Metformin; Mice; Thioctic Acid | 2019 |